2H-Pyran, tetrahydro, 3,5-dichloro, # 1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2H-Pyran, tetrahydro, 3,5-dichloro, # 1
• 英文别名: 3,5-dichlorooxane
• 化学式: C₅H₈Cl₂O
• 分子量: 155.02
• InChiKey: CQFLTXQOHZLTRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants
  申请人：——

  公开号：US20040181094A1

  公开（公告）日：2004-09-16

  A method is provided for synthesizing substituted alkynes from an alkyne reactant and a nucleophile using rhenium (V) oxo complex as a catalyst. The alkyne reactant is substituted at the propargylic position with a leaving group susceptible to displacement by the nucleophile in a nucleophilic substitution reaction. The method involves contacting the alkyne reactant with a nucleophilic reactant in the presence of a catalytically effective amount of the rhenium (V) oxo complex. The method does not require activation of the leaving group or ionization of the nucleophilic reactant, and may be carried out in the presence of air and moisture. The invention is useful in synthesizing propargyl ethers, propargyl amines, and the like.

  本方法提供了一种使用铼（V）氧配合物作为催化剂从炔烃反应物和亲核试剂中合成取代炔烃的方法。炔烃反应物在丙炔位置上被取代，带有易被亲核取代反应中的亲核试剂排斥的离开基。该方法涉及将炔烃反应物与亲核反应物接触，在铼（V）氧配合物的催化下进行反应。该方法不需要激活离开基或离子化亲核反应物，并且可以在空气和水分存在的情况下进行。本发明对于合成丙烯基醚、丙烯基胺等物质是有用的。
• CRF RECEPTOR ANTAGONISTS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1383498A1

  公开（公告）日：2004-01-28
• [EN] CRF RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CRF
  申请人：GLAXO GROUP LTD

  公开号：WO2002087573A1

  公开（公告）日：2002-11-07

  The present invention relates to tricyclic pyrimidines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereofwherein R is aryl or heteroaryl, wherein each of the above groups R may be substituted by 1 to 4 substituents indendently selected from the group consisting of:halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, C1-C6 mono or dialkylamino, nitro, cyano and a group R4; R1 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, NH2, halogen or cyano; R2 is hydrogen or C(H)n(R5)q(CH2)pZR6; R3 is hydrogen, C2-C6 alkenyl, C2-C6 alkynyl or [CH(R5)(CH2)p]mZR6; R4 is C3-C7 cycloalkyl, which may contain one or more double bonds; aryl; or a 5-6 membered heterocycle; wherein each of the above groups R4 may be substituted by one or more groups selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, C1-C6 mon a or dialkylamino, nitro, and cyano; R5 is hydrogen, C2-C6 alkenyl, C2-C6 alkynyl or (CH2)pZR6; R6 is C1-C6 alkyl, which may be substituted by one or more groups selected from halogen, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, C1-C6 alkoxy, C1-C6 mono or dialkylamino, nitro, cyano and a group R4; Y and X are independently carbon or nitrogen; m and n are independently 0 or 1; p is 0 or an integer from 1 to 4;q is 1 or 2;Z is a bond, O, NH or S;to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).